

Ludwig Presence at 2017 ASCO Annual Meeting

Ludwig Scientist(s)	Affiliation(s)	Session Date/ Time	Location	Session Type	Session Title	Presentation/Abstract Title & Time
FRIDAY, JUNE 2						
Jedd Wolchok, Alexandra Snyder Charen, Margaret Callahan**	Ludwig MSK	2:45pm-4:15pm	Arie Crown Theater	Clinical Science Symposium	Expanding the Actionable Landscape: Bladder Cancer Genomics	DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC).
Ross Donehower	Ludwig Johns Hopkins	N/A	N/A	President's Dinner	ASCO's Excellence in Teaching Award	Award recipient
SATURDAY, JUNE 3						
Jeanne Tie*, Joshua Cohen, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein, Peter Gibbs**	Ludwig Johns Hopkins, Ludwig collaborators	8:00am-11:30am	Hall A (Board #144)	Poster Session	Gastrointestinal (Colorectal) Cancer	The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).
Joshua Cohen, Jeanne Tie, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Peter Gibbs**	Ludwig Johns Hopkins, Ludwig collaborators	8:00am-11:30am	Hall A (Board #93)	Poster Session	Gastrointestinal (Noncolorectal) Cancer	Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer.
Ash Alizadeh, Maximilian Diehn**	Ludwig Stanford	8:00am-11:30am	Hall A (Board #47)	Poster Session	Gastrointestinal (Noncolorectal) Cancer	Circulating tumor DNA analysis for outcome prediction in localized esophageal cancer.

*scientist is lead author

**scientist is senior author

Ludwig Presence at 2017 ASCO Annual Meeting

Ash Alizadeh**, Maximilian Diehn**	Ludwig Stanford	8:00am-11:30am	Hall A (Board #255)	Poster Session	Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia	Analysis of circulating tumor DNA in localized lung cancer for detection of molecular residual disease and personalization of adjuvant strategies.
Michael Postow**	Ludwig MSK	1:15pm-4:45pm	Hall A (Board #156)	Poster Session	Melanoma/Skin Cancers	Outcomes of patients with melanoma who discontinue immunotherapy.
Stephen Hodi**	Ludwig Harvard	1:15pm-4:45pm	Hall A (Board #129)	Poster Session	Melanoma/Skin Cancers	Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: Identifying markers for clinical outcome and treatments decisions.
George Demetri**	Ludwig Harvard	1:15pm-4:45pm	Hall A (Board #213)	Poster Session	Tumor Biology	Whole exome analysis of patients with metastatic GIST demonstrating exceptional survival with imatinib therapy compared to those with short term benefit.
Stephen Hodi**	Ludwig Harvard	1:15pm-4:45pm	Hall A (Board #123)	Poster Session	Melanoma/Skin Cancers	Association of distinct baseline tissue biomarkers with response to nivolumab (NIVO) and Ipilimumab (IPI) in melanoma: CheckMate 064.
Michael Postow*, Danielle McCabe, Mary Macri, Paul Schwarzenberger, Toni Ricciardi, Aileen Ryan, Ralph Venhaus	Ludwig MSK, Ludwig Clinical Trials Management	1:15pm-4:45pm	Hall A (Board #199a)	Poster Session	Melanoma/Skin Cancers	Phase 1 study to evaluate safety and efficacy of ipilimumab + nivolumab + external beam radiotherapy in patients with metastatic melanoma.

*scientist is lead author

**scientist is senior author

Ludwig Presence at 2017 ASCO Annual Meeting

Ash Alizadeh**, Maximilian Diehn**	Ludwig Stanford	3:00pm-6:00pm	S100bc	Oral Abstract Session	Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia	Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma.
SUNDAY, JUNE 4						
Crystal Mackall**	Ludwig Stanford	8:00am-11:30am	Hall A (Board #283)	Poster Session	Pediatric Oncology	ADVL1412: Initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors—A COG study.
MONDAY, JUNE 5						
George Demetri	Ludwig Harvard	1:15pm-2:45pm	E450ab	Clinical Science Symposium	GIST: Imatinib and Beyond	1:51pm - 2:03pm: GIST: To Sequence or Not to Sequence?
Margaret Callahan*, Andrew Park, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus, Jedd Wolchok**	Ludwig MSK; Ludwig Clinical Trials Management	8:00am-11:30am	Hall A (Board #164)	Poster Session	Developmental Therapeutics—Immunotherapy	Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors.
Ash Alizadeh*, Maximilian Diehn*	Ludwig Stanford	8:00am-11:30am	Hall A (Board #300)	Poster Session	Hematologic Malignancies — Lymphoma and Chronic Lymphocytic Leukemia	Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA.

*scientist is lead author

**scientist is senior author

Ludwig Presence at 2017 ASCO Annual Meeting

Alexander Lesokhin*, Lisa Shohara, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus**	Ludwig MSK; Ludwig Clinical Trials Management	8:00am-11:30am	Hall A (Board #377a)	Poster Session	Hematologic Malignancies—Plasma Cell Dyscrasia	Phase 1 study to evaluate the safety and efficacy of immunotherapy with tremelimumab and durvalumab in multiple myeloma patients receiving high dose chemotherapy and autologous stem cell transplant (HDT/ASCT) + peripheral blood lymphocyte (PBL) reinfusion.
Daniel Dasilva, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus**	Ludwig Clinical Trials Management	8:00am-11:30am	Hall A (Board #193b)	Poster Session	Developmental Therapeutics—Immunotherapy	Phase 1/2 study of in situ vaccination with tremelimumab + intravenous (IV) durvalumab + poly ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors.
Crystal Mackall*	Ludwig Stanford	1:15pm-4:15pm	Hall D1	Oral Abstract	Developmental Therapeutics—Immunotherapy	Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2+ patients with synovial sarcoma (NCT01343043).
Andrew Park, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus**	Ludwig Clinical Trials Management	1:15pm-4:45pm	Hall A (Board #284)	Poster Session	Central Nervous System Tumors	Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.

*scientist is lead author

**scientist is senior author

PUBLICATION-ONLY						
Dmitriy Zamarin*	Ludwig MSK	N/A	N/A	Publication-only abstract	N/A	Early clinical progression in patients with gynecologic malignancies receiving immunomodulatory antibody therapy.

*scientist is lead author

**scientist is senior author